ImmuneOncia Therapeutics Inc.   Report issue

For profit Phase 1 Phase 2
Founded: Seongnam Korea, Republic of (2016)

Organization Overview

First Clinical Trial
2018
NCT03644056
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

ImmuneOncia Therapeutics Inc.

Active Ingredients

Drugs in Phase 2 Trials (1)

imc001 (2 trials)

Drugs in Phase 1 Trials (1)

imc-002 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Lymphoma (Phase 2)

Lymphoma, Extranodal NK-T-Cell (Phase 2)

Lymphoma, T-Cell (Phase 2)

Neoplasm Metastasis (Phase 1)

Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 2